Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Account Payables: 2010-2025

Historic Change in Account Payables for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to -$15.4 million.

  • Arrowhead Pharmaceuticals' Change in Account Payables fell 84.79% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 213.55%. This contributed to the annual value of $6.3 million for FY2025, which is 213.55% up from last year.
  • As of Q3 2025, Arrowhead Pharmaceuticals' Change in Account Payables stood at -$15.4 million, which was down 165.77% from $23.4 million recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' Change in Account Payables' 5-year high stood at $28.0 million during Q3 2023, with a 5-year trough of -$15.4 million in Q3 2025.
  • Moreover, its 3-year median value for Change in Account Payables was $3.1 million (2024), whereas its average is $3.3 million.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Change in Account Payables surged by 1,284.53% in 2022 and then plummeted by 501.50% in 2023.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' Change in Account Payables stood at -$5.4 million in 2021, then spiked by 61.55% to -$2.1 million in 2022, then plummeted by 501.50% to -$12.5 million in 2023, then skyrocketed by 124.62% to $3.1 million in 2024, then plummeted by 84.79% to -$15.4 million in 2025.
  • Its Change in Account Payables stands at -$15.4 million for Q3 2025, versus $23.4 million for Q2 2025 and -$4.8 million for Q1 2025.